PolyNovo Limited Logo

PolyNovo Limited

PNV.AX

(0.5)
Stock Price

2,02 AUD

4.86% ROA

7.45% ROE

322.75x PER

Market Cap.

1.699.259.760,00 AUD

4.54% DER

0% Yield

5.1% NPM

PolyNovo Limited Stock Analysis

PolyNovo Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PolyNovo Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (62%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

3 ROE

The stock's ROE indicates a negative return (-5.95%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-3.55%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (51.67x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-77) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

PolyNovo Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PolyNovo Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

PolyNovo Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PolyNovo Limited Revenue
Year Revenue Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 836 100%
2005 0 0%
2006 178 100%
2007 4.366 95.92%
2008 0 0%
2009 0 0%
2010 121.910 100%
2011 388.201 68.6%
2012 0 0%
2013 112.565 100%
2014 60.196 -87%
2015 22.339 -169.47%
2016 3.277.204 99.32%
2017 3.620.126 9.47%
2018 6.553.852 44.76%
2019 14.043.822 53.33%
2020 22.156.123 36.61%
2020 22.156.123 0%
2021 29.157.924 24.01%
2022 41.439.839 29.64%
2023 65.241.468 36.48%
2024 224.172.000 70.9%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PolyNovo Limited Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 3.996.000 100%
2003 8.013.887 50.14%
2004 10.433.074 23.19%
2005 8.958.840 -16.46%
2006 252.135 -3453.19%
2007 241.616 -4.35%
2008 150.952 -60.06%
2009 176.830 14.63%
2010 466.735 62.11%
2011 871.024 46.42%
2012 1.299.926 32.99%
2013 847.473 -53.39%
2014 1.091.240 22.34%
2015 1.038.670 -5.06%
2016 2.698.557 61.51%
2017 3.136.002 13.95%
2018 3.806.108 17.61%
2019 3.248.426 -17.17%
2020 2.352.698 -38.07%
2020 2.352.698 0%
2021 3.647.424 35.5%
2022 5.747.156 36.54%
2023 7.428.821 22.64%
2024 24.228.000 69.34%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PolyNovo Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 419.044 100%
2002 6.000 -6884.07%
2003 1.141.242 99.47%
2004 778.633 -46.57%
2005 2.365.415 67.08%
2006 3.564.293 33.64%
2007 4.431.341 19.57%
2008 2.850.502 -55.46%
2009 1.833.352 -55.48%
2010 1.980.470 7.43%
2011 1.984.345 0.2%
2012 2.083.589 4.76%
2013 1.690.289 -23.27%
2014 2.156.723 21.63%
2015 2.262.989 4.7%
2016 3.431.006 34.04%
2017 5.980.575 42.63%
2018 7.796.560 23.29%
2019 11.866.868 34.3%
2020 19.565.275 39.35%
2020 19.565.275 0%
2021 24.054.508 18.66%
2022 28.575.543 15.82%
2023 50.844.924 43.8%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PolyNovo Limited EBITDA
Year EBITDA Growth
1999 -1.628.224
2000 -3.550.888 54.15%
2001 -5.051.003 29.7%
2002 -2.502.000 -101.88%
2003 -9.155.129 72.67%
2004 -12.196.416 24.94%
2005 -11.324.255 -7.7%
2006 -12.297.093 7.91%
2007 -13.664.279 10.01%
2008 -4.785.721 -185.52%
2009 -2.528.512 -89.27%
2010 -2.487.798 -1.64%
2011 -3.624.902 31.37%
2012 -4.083.671 11.23%
2013 -3.205.351 -27.4%
2014 -2.935.395 -9.2%
2015 -2.796.443 -4.97%
2016 -3.306.452 15.42%
2017 -4.897.949 32.49%
2018 -5.706.502 14.17%
2019 -2.832.963 -101.43%
2020 -3.271.921 13.42%
2020 -3.303.120 0.94%
2021 -2.031.170 -62.62%
2022 1.540.830 231.82%
2023 -3.902.470 139.48%
2024 8.716.000 144.77%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PolyNovo Limited Gross Profit
Year Gross Profit Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 836 100%
2005 0 0%
2006 178 100%
2007 4.366 95.92%
2008 0 0%
2009 0 0%
2010 121.910 100%
2011 388.201 68.6%
2012 0 0%
2013 -614.030 100%
2014 -71.812 -755.05%
2015 -197.049 63.56%
2016 1.425.465 113.82%
2017 2.202.907 35.29%
2018 2.114.885 -4.16%
2019 9.501.250 77.74%
2020 20.452.602 53.55%
2020 5.008.236 -308.38%
2021 7.826.254 36.01%
2022 16.228.825 51.78%
2023 19.332.100 16.05%
2024 77.928.000 75.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PolyNovo Limited Net Profit
Year Net Profit Growth
1999 -1.635.642
2000 -3.563.405 54.1%
2001 -5.071.000 29.73%
2002 -5.731.000 11.52%
2003 -8.570.079 33.13%
2004 0 0%
2005 -10.764.589 100%
2006 -11.293.869 4.69%
2007 -13.406.939 15.76%
2008 -4.441.167 -201.88%
2009 -1.830.175 -142.66%
2010 -1.861.559 1.69%
2011 -2.917.137 36.19%
2012 -2.699.475 -8.06%
2013 -1.492.423 -80.88%
2014 -2.936.379 49.17%
2015 -1.302.446 -125.45%
2016 -3.061.874 57.46%
2017 -5.006.014 38.84%
2018 -5.974.132 16.21%
2019 -3.189.893 -87.28%
2020 -4.193.738 23.94%
2020 -4.193.737 -0%
2021 -4.605.032 8.93%
2022 -1.192.532 -286.16%
2023 -4.924.539 75.78%
2024 10.268.000 147.96%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PolyNovo Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 -1
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PolyNovo Limited Free Cashflow
Year Free Cashflow Growth
1999 -12.059
2000 -8.595 -40.3%
2001 -34.000 74.72%
2002 -296.000 88.51%
2003 -76.615 -286.35%
2004 -491.126 84.4%
2005 -478.950 -2.54%
2006 -170.778 -180.45%
2007 -138.435 -23.36%
2008 -16.085 -760.65%
2009 -591.970 97.28%
2010 -136.991 -332.12%
2011 -472.518 71.01%
2012 -57.618 -720.09%
2013 -2.339.748 97.54%
2014 -2.689.170 12.99%
2015 -2.884.710 6.78%
2016 -3.761.108 23.3%
2017 -5.743.278 34.51%
2018 -7.097.940 19.09%
2019 -9.889.937 28.23%
2020 -9.271.783 -6.67%
2021 -3.817.454 -142.88%
2022 -2.548.562 -49.79%
2023 -7.461.296 65.84%
2024 2.144.000 448.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PolyNovo Limited Operating Cashflow
Year Operating Cashflow Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -2.325.918 100%
2014 -2.612.850 10.98%
2015 -2.567.281 -1.77%
2016 -3.556.419 27.81%
2017 -5.161.533 31.1%
2018 -6.877.961 24.96%
2019 -3.369.733 -104.11%
2020 -402.564 -737.07%
2021 -248.737 -61.84%
2022 -2.056.633 87.91%
2023 -5.933.067 65.34%
2024 3.929.000 251.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PolyNovo Limited Capital Expenditure
Year Capital Expenditure Growth
1999 12.059
2000 8.595 -40.3%
2001 34.000 74.72%
2002 296.000 88.51%
2003 76.615 -286.35%
2004 491.126 84.4%
2005 478.950 -2.54%
2006 170.778 -180.45%
2007 138.435 -23.36%
2008 16.085 -760.65%
2009 591.970 97.28%
2010 136.991 -332.12%
2011 472.518 71.01%
2012 57.618 -720.09%
2013 13.830 -316.62%
2014 76.320 81.88%
2015 317.429 75.96%
2016 204.689 -55.08%
2017 581.745 64.81%
2018 219.979 -164.45%
2019 6.520.204 96.63%
2020 8.869.219 26.49%
2021 3.568.717 -148.53%
2022 491.929 -625.45%
2023 1.528.229 67.81%
2024 1.785.000 14.38%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PolyNovo Limited Equity
Year Equity Growth
1999 6.655.299
2000 11.458.422 41.92%
2001 6.408.197 -78.81%
2002 12.148.571 47.25%
2003 6.261.207 -94.03%
2004 16.684.516 62.47%
2005 17.281.740 3.46%
2006 22.764.614 24.09%
2007 20.788.032 -9.51%
2008 16.461.066 -26.29%
2009 15.822.858 -4.03%
2010 13.741.844 -15.14%
2011 10.640.479 -29.15%
2012 7.988.617 -33.2%
2013 7.817.880 -2.18%
2014 8.668.011 9.81%
2015 7.393.306 -17.24%
2016 15.111.726 51.08%
2017 10.812.866 -39.76%
2018 28.458.970 62.01%
2019 26.099.479 -9.04%
2020 23.812.024 -9.61%
2021 22.352.045 -6.53%
2022 17.715.086 -26.18%
2023 65.383.142 72.91%
2024 72.124.000 9.35%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PolyNovo Limited Assets
Year Assets Growth
1999 7.077.935
2000 11.962.309 40.83%
2001 7.222.797 -65.62%
2002 12.614.331 42.74%
2003 7.474.346 -68.77%
2004 18.651.033 59.93%
2005 18.686.235 0.19%
2006 24.948.501 25.1%
2007 22.017.251 -13.31%
2008 17.162.756 -28.29%
2009 17.287.778 0.72%
2010 15.021.442 -15.09%
2011 11.771.471 -27.61%
2012 8.909.102 -32.13%
2013 8.618.688 -3.37%
2014 9.413.718 8.45%
2015 8.125.790 -15.85%
2016 16.024.868 49.29%
2017 12.055.864 -32.92%
2018 29.821.925 59.57%
2019 28.228.515 -5.64%
2020 37.856.941 25.43%
2021 38.339.298 1.26%
2022 34.971.530 -9.63%
2023 92.620.649 62.24%
2024 109.167.000 15.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PolyNovo Limited Liabilities
Year Liabilities Growth
1999 422.636
2000 503.887 16.12%
2001 814.600 38.14%
2002 465.760 -74.9%
2003 1.213.139 61.61%
2004 1.966.517 38.31%
2005 1.404.495 -40.02%
2006 2.183.887 35.69%
2007 1.229.219 -77.66%
2008 701.690 -75.18%
2009 1.464.920 52.1%
2010 1.279.598 -14.48%
2011 1.130.992 -13.14%
2012 920.485 -22.87%
2013 800.808 -14.94%
2014 745.707 -7.39%
2015 732.484 -1.81%
2016 913.143 19.78%
2017 1.242.998 26.54%
2018 1.362.955 8.8%
2019 2.129.036 35.98%
2020 14.044.917 84.84%
2021 15.987.253 12.15%
2022 17.256.444 7.35%
2023 27.237.507 36.64%
2024 37.043.000 26.47%

PolyNovo Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.15
Net Income per Share
0.01
Price to Earning Ratio
322.75x
Price To Sales Ratio
16.47x
POCF Ratio
333.59
PFCF Ratio
774.86
Price to Book Ratio
23.54
EV to Sales
16.17
EV Over EBITDA
546.05
EV to Operating CashFlow
327.85
EV to FreeCashFlow
760.94
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
1,70 Bil.
Enterprise Value
1,67 Bil.
Graham Number
0.13
Graham NetNet
0.04

Income Statement Metrics

Net Income per Share
0.01
Income Quality
0.97
ROE
0.07
Return On Assets
0.05
Return On Capital Employed
0.01
Net Income per EBT
3.07
EBT Per Ebit
1.99
Ebit per Revenue
0.01
Effective Tax Rate
-2.07

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.11
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.35
Operating Profit Margin
0.01
Pretax Profit Margin
0.02
Net Profit Margin
0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.01
Free CashFlow per Share
0
Capex to Operating CashFlow
0.57
Capex to Revenue
0.03
Capex to Depreciation
1.32
Return on Invested Capital
0.04
Return on Tangible Assets
0.05
Days Sales Outstanding
74.51
Days Payables Outstanding
34.77
Days of Inventory on Hand
48.8
Receivables Turnover
4.9
Payables Turnover
10.5
Inventory Turnover
7.48
Capex per Share
0

Balance Sheet

Cash per Share
0,07
Book Value per Share
0,10
Tangible Book Value per Share
0.1
Shareholders Equity per Share
0.1
Interest Debt per Share
0.01
Debt to Equity
0.05
Debt to Assets
0.03
Net Debt to EBITDA
-9.99
Current Ratio
3.41
Tangible Asset Value
0,07 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
81123000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
7930000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PolyNovo Limited Dividends
Year Dividends Growth

PolyNovo Limited Profile

About PolyNovo Limited

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

CEO
Mr. Swami Raote BPHARM, M.B.A
Employee
254
Address
320 Lorimer Street
Port Melbourne, 3207

PolyNovo Limited Executives & BODs

PolyNovo Limited Executives & BODs
# Name Age
1 Mr. Jan-Marcel Gielen C.A.
Chief Financial Officer
70
2 Mr. David N. Morris BAppSc, BBus
President of Asia Pacific
70
3 Mr. Philip Scorgie
Chief Information Officer
70
4 Ms. Ingrid Anderson
Chief People Officer
70
5 Dr. Joseph F. Amaral M.D.
Chief Medical Officer
70
6 Mr. Edward Graubart
President of North America
70
7 Mr. Lior Harel
General Counsel & Company Secretary
70
8 Mr. Swami Raote BPHARM, M.B.A.
Chief Executive Officer & Director
70
9 Dr. David McQuillan Ph.D.
Chief Technical & Scientific Officer
70
10 Mr. Ahmed Hassan
Director of Operations
70

PolyNovo Limited Competitors

AVITA Medical, Inc. Logo
AVITA Medical, Inc.

AVH.AX

(0.5)
Nanosonics Limited Logo
Nanosonics Limited

NAN.AX

(1.5)
Pro Medicus Limited Logo
Pro Medicus Limited

PME.AX

(4.0)
EML Payments Limited Logo
EML Payments Limited

EML.AX

(1.2)
Megaport Limited Logo
Megaport Limited

MP1.AX

(1.0)